DaVita HealthCare Reaches New 52-Week High (DVA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- DaVita HealthCare Partners (NYSE: DVA) hit a new 52-week high Tuesday as it is currently trading at $115.06, above its previous 52-week high of $114.85 with 480,072 shares traded as of 12 p.m. ET. Average volume has been 778,500 shares over the past 30 days.

DaVita HealthCare has a market cap of $10.64 billion and is part of the health care sector and health services industry. Shares are up 47.1% year to date as of the close of trading on Monday.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company has a P/E ratio of 20.2, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates DaVita HealthCare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, growth in earnings per share, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full DaVita HealthCare Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy It Like Buffett -- or Better

Buy It Like Buffett -- or Better